Estimating the threat posed by prostate cancer. - Suppr | 超能文献

Estimating the threat posed by prostate cancer.

作者信息

Albertsen Peter C

机构信息

Division of Urology, University of Connecticut Health Center, Farmington, CT, USA.

出版信息

BJU Int. 2020 Apr;125(4):480-481. doi: 10.1111/bju.15021.

DOI:10.1111/bju.15021

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Estimating the threat posed by prostate cancer.

BJU Int. 2020 Apr;125(4):480-481. doi: 10.1111/bju.15021.

2

The relationship between prostate specific antigen change and biopsy progression in patients on active surveillance for prostate cancer.在对前列腺癌进行主动监测的患者中，前列腺特异性抗原变化与活检进展之间的关系。

J Urol. 2011 May;185(5):1656-60. doi: 10.1016/j.juro.2010.12.042. Epub 2011 Mar 21.

3

Observational studies and the natural history of screen-detected prostate cancer.筛查发现的前列腺癌的观察性研究及自然史

Curr Opin Urol. 2015 May;25(3):232-7. doi: 10.1097/MOU.0000000000000157.

4

Ability of 2 pretreatment risk assessment methods to predict prostate cancer recurrence after radical prostatectomy: data from CaPSURE.两种术前风险评估方法预测前列腺癌根治术后复发的能力：来自CaPSURE的数据。

J Urol. 2005 Apr;173(4):1126-31. doi: 10.1097/01.ju.0000155535.25971.de.

5

Prognostic factors in patients with prostate cancer refractory to endocrine therapy: univariate and multivariate analyses including doubling times of prostate-specific antigen and prostatic acid phosphatase.内分泌治疗难治性前列腺癌患者的预后因素：单因素和多因素分析，包括前列腺特异性抗原和前列腺酸性磷酸酶的倍增时间

Jpn J Clin Oncol. 1997 Aug;27(4):258-62. doi: 10.1093/jjco/27.4.258.

6

The era of active surveillance for low-risk.Prostate cancer is here.低风险前列腺癌主动监测的时代已经到来。

Arch Esp Urol. 2016 Mar;69(2):49-51.

7

Role of immediate confirmatory prostate biopsy to ensure accurate eligibility for active surveillance.立即行确认性前列腺活检在确保准确符合主动监测条件中的作用。

Urology. 2012 Nov;80(5):1070-4. doi: 10.1016/j.urology.2012.07.049.

8

Prediagnostic prostate-specific antigen kinetics and the risk of biopsy progression in active surveillance patients.诊断前前列腺特异性抗原动力学与主动监测患者活检进展风险

Int J Urol. 2016 Apr;23(4):313-7. doi: 10.1111/iju.13048. Epub 2016 Jan 13.

9

Limitations and use of PSA velocity in the diagnosis and characterization of prostate cancer.前列腺特异性抗原（PSA）速度在前列腺癌诊断和特征描述中的局限性及应用

Nat Clin Pract Urol. 2007 Nov;4(11):576-7. doi: 10.1038/ncpuro0936. Epub 2007 Sep 25.

10

Limitations and use of PSA derivatives in the screening and risk stratification of prostate cancer.前列腺特异性抗原（PSA）衍生物在前列腺癌筛查和风险分层中的局限性及应用

Urol Oncol. 2009 Nov-Dec;27(6):583-4. doi: 10.1016/j.urolonc.2009.06.011.

引用本文的文献

1

Unveiling poly(rC)-binding protein 2 as the target protein for curcusone C against prostate cancer: mechanism validation through click chemistry-activity based proteomics profiling approach.揭示聚（rC）结合蛋白 2 为 curcusone C 针对前列腺癌的靶蛋白：通过点击化学-基于活性的蛋白质组学分析方法进行机制验证。

BMC Cancer. 2023 Oct 9;23(1):957. doi: 10.1186/s12885-023-11467-0.